Paradigmia
⌕Sign in ↗
Lessons

Immunotherapy in organ transplantation

Created by: Alfredo Corell

Although there are many genetic differences between two unrelated individuals, only a few are especially relevant in triggering an immune rejection response.

  • In the case of blood transfusions (the simplest form of transplant), the alloantigens that determine compatibility between donor and recipient are the ABO antigens and Rh, present on erythrocytes. That is, ABO and Rh compatibility is sought, not HLA.
  • In cornea transplantation there is no need for compatibility; the donor is always a cadaver.
  • Transplantation of skin is always an autotransplant.
  • Among solid organs, the kidney has the best compatibility, whether from a cadaveric or a living donor.
  • In heart and lung transplantation there is no time to carry out HLA compatibility testing and the organ always comes from a cadaver.
  • The same occurs with the liver; independent liver lobes are now transplanted from living donors.
  • For bone marrow transplantation, very high compatibility is necessary. Donor banks are always interconnected, but it is very difficult to find a 100% compatible donor.

In organ and tissue transplantation, the immune response is directed especially against histocompatibility antigens belonging to the HLA system, which are highly polymorphic.

The great majority of transplants (except those between monozygotic twins) are performed under conditions of some degree of incompatibility, so we must always resort to the administration of immunosuppressive drugs that prevent the rejection reaction.

Effect of HLA compatibility on the long-term survival of kidney grafts. The effect is moderate at five years but increases in the long term. The effect is even greater in re-transplants.

Immunosuppression

The best treatment for rejection is prevention, but if this cannot be achieved, immunosuppressive drugs are used. Immunity has to be suppressed, but some defences must be left.

The general treatment is steroids: corticosteroids are lipid-soluble compounds that can enter cells through the plasma membrane and bind to their receptors in the cell cytoplasm. As a result, the receptor separates from the Hsp90 dimer (heat-shock protein) and is now able to cross the nuclear membrane. Inside the nucleus, the receptor binds to gene sequences that suppress immunity.

  • Ciclosporins: such as ciclosporin A and tacrolimus, act on B and T lymphocytes and on cells of innate immunity and alter intercellular calcium uptake by blocking calcium-dependent enzymes. They block the activation cascade. There are other drugs that block the cell cycle.
  • Monoclonal antibodies: they try to halt the proliferation of lymphocytes that act against the transplant. The anti-CD3 antibody is the most widely used, and it blocks only T lymphocytes. You do not remove lymphocytes; you block their activation.

It can be said that anti-CD3 monoclonals attack T cells, whereas anti-CD25 monoclonals attack activated T cells (it is currently the most specific).

There are five pharmacological steps for immunosuppression:

  1. Corticosteroids: prednisolone and hydrocortisone.
  2. Calcineurin inhibitors: ciclosporin A and tacrolimus.
  3. mTOR inhibitors: sirolimus (rapamycin), a macrolide antibiotic, and everolimus.
  4. Antiproliferatives: azathioprine and mycophenolic acid (MPA).
  5. Monoclonal antibodies: anti-CD3 and anti-CD25 (IL-2 receptor).

These are not all given at once; instead a combination of three drugs is used, from groups 1, 2 and 4. This therapy has been used for many years under the name of triple therapy.

If the patient responds well, that is all that is needed; if not, the drugs are changed. Over time they are alternated to ensure there is no rejection, but causing as little immunosuppression as possible.

Your study

Select a passage in the lesson. Your highlights are private.

0Back to course →
Keep exploring

Knowledge does not end here.

Paradigmia · YouTube ↗